|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mattiuzzi C and Lippi G: Current cancer
epidemiology. J Epidemiol Glob Health. 9:217–222. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Britton C, Laing R and Devaney E: Small
RNAs in parasitic nematodes-forms and functions. Parasitology.
147:855–864. 2020. View Article : Google Scholar
|
|
4
|
Morales-Martínez M and Vega MI: Role of
MicroRNA-7 (MiR-7) in cancer physiopathology. Int J Mol Sci.
23:90912022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hebbar S, Panzade G, Vashisht AA,
Wohlschlegel JA, Veksler-Lublinsky I and Zinovyeva AY: Functional
identification of microRNA-centered complexes in C: elegans. Sci
Rep. 12:71332022. View Article : Google Scholar
|
|
6
|
Hill M and Tran N: miRNA interplay:
Mechanisms and consequences in cancer. Dis Model Mech.
14:dmm0476622021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen Y and Wang X: miRDB: An online
database for prediction of functional microRNA targets. Nucleic
Acids Res. 48(D1): D127–D131. 2020. View Article : Google Scholar :
|
|
8
|
Wang Y, Xing QF, Liu XQ, Guo ZJ, Li CY and
Sun G: MiR-122 targets VEGFC in bladder cancer to inhibit tumor
growth and angiogenesis. Am J Transl Res. 8:3056–3066.
2016.PubMed/NCBI
|
|
9
|
Chun KH: Molecular Targets and signaling
pathways of microRNA-122 in hepatocellular carcinoma.
Pharmaceutics. 14:13802022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Collison AM, Sokulsky LA, Kepreotes E,
Pereira de Siqueira A, Morten M, Edwards MR, Walton RP, Bartlett
NW, Yang M, Nguyen TH, et al: miR-122 promotes virus-induced lung
disease by targeting SOCS1. JCI Insight. 6:e1279332021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang M, Zheng H, Zhou X, Zhang J and Shao
G: miR-122 promotes diabetic retinopathy through targeting TIMP3.
Anim Cells Syst (Seoul). 24:275–281. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Scott KM, Cohen DJ, Boyan BD and Schwartz
Z: miR-122 and the WNT/β-catenin pathway inhibit effects of both
interleukin-1β and tumor necrosis factor-α in articular
chondrocytes in vitro. J Cell Biochem. 123:1053–1063. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li A, Wu J, Zhai A, Qian J, Qian J, Wang
X, Qaria MA, Zhang Q, Li Y, Fang Y, Kao W, et al: HBV triggers
APOBEC2 expression through miR-122 regulation and affects the
proliferation of liver cancer cells. Int J Oncol. 55:1137–1148.
2019.PubMed/NCBI
|
|
14
|
Smolarz B, Durczyński A, Romanowicz H,
Szyłło K and Hogendorf P: miRNAs in cancer (review of literature).
Int J Mol Sci. 23:28052022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Y, Song JW, Lin JY, Miao R and Zhong
JC: Roles of MicroRNA-122 in cardiovascular fibrosis and related
diseases. Cardiovasc Toxicol. 20:463–473. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo L, Yin M and Wang Y: CREB1, a direct
target of miR-122, promotes cell proliferation and invasion in
bladder cancer. Oncol Lett. 16:3842–3848. 2018.PubMed/NCBI
|
|
17
|
Qin H, Sha J, Jiang C, Gao X, Qu L, Yan H,
Xu T, Jiang Q and Gao H: miR-122 inhibits metastasis and
epithelial-mesenchymal transition of non-small-cell lung cancer
cells. Onco Targets Ther. 8:3175–3184. 2015.PubMed/NCBI
|
|
18
|
Chandimali N, Huynh DL, Zhang JJ, Lee JC,
Yu DY, Jeong DK and Kwon T: MicroRNA-122 negatively associates with
peroxiredoxin-II expression in human gefitinib-resistant lung
cancer stem cells. Cancer Gene Ther. 26:292–304. 2019. View Article : Google Scholar :
|
|
19
|
Kong L, Wu Q, Zhao L, Ye J, Li N and Yang
H: Upregulated lncRNA-UCA1 contributes to metastasis of bile duct
carcinoma through regulation of miR-122/CLIC1 and activation of the
ERK/MAPK signaling pathway. Cell Cycle. 18:1212–1228. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang Y, Li Q and Guo L: MicroRNA-122 acts
as tumor suppressor by targeting TRIM29 and blocking the activity
of PI3K/AKT signaling in nasopharyngeal carcinoma in vitro. Mol Med
Rep. 17:8244–8252. 2018.PubMed/NCBI
|
|
21
|
Liao B, Wang Z, Zhu Y, Wang M and Liu Y:
Long noncoding RNA DRAIC acts as a microRNA-122 sponge to
facilitate nasopharyngeal carcinoma cell proliferation, migration
and invasion via regulating SATB1. Artif Cells Nanomed Biotechnol.
47:3585–3597. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu H, Hou T, Ju W, Xing Y, Zhang X and
Yang J: MicroRNA-122 downregulates Rho-associated protein kinase 2
expression and inhibits the proliferation of prostate carcinoma
cells. Mol Med Rep. 19:3882–3888. 2019.PubMed/NCBI
|
|
23
|
Perez-Añorve IX, Gonzalez-De la Rosa CH,
Soto-Reyes E, Beltran-Anaya FO, Del Moral-Hernandez O,
Salgado-Albarran M, Angeles-Zaragoza O, Gonzalez-Barrios JA,
Landero-Huerta DA and Chavez-Saldaña M: New insights into
radioresistance in breast cancer identify a dual function of
miR-122 as a tumor suppressor and oncomiR. Mol Oncol. 13:1249–1267.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Y and Tang L: Inhibition of breast
cancer cell proliferation and tumorigenesis by long non-coding RNA
RPPH1 down-regulation of miR-122 expression. Cancer Cell Int.
17:1092017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li XN, Yang H and Yang T: miR-122 inhibits
hepatocarcinoma cell progression by targeting LMNB2. Oncol Res.
28:41–49. 2020. View Article : Google Scholar
|
|
26
|
Iino I, Kikuchi H, Miyazaki S, Hiramatsu
Y, Ohta M, Kamiya K, Kusama Y, Baba S, Setou M and Konno H: Effect
of miR-122 and its target gene cationic amino acid transporter 1 on
colorectal liver metastasis. Cancer Sci. 104:624–630. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hua Y, Zhu Y, Zhang J, Zhu Z, Ning Z, Chen
H, Liu L, Chen Z and Meng Z: miR-122 targets X-linked inhibitor of
apoptosis protein to sensitize oxaliplatin-resistant colorectal
cancer cells to oxaliplatin-mediated cytotoxicit. Cell Physiol
Biochem. 51:2148–2159. 2018. View Article : Google Scholar
|
|
28
|
Wang J, Yu PY, Yu JP, Luo JD, Sun ZQ, Sun
F, Kong Z and Wang JL: KIF22 promotes progress of esophageal
squamous cell carcinoma cells and is negatively regulated by
miR-122. Am J Transl Res. 13:4152–4166. 2021.PubMed/NCBI
|
|
29
|
Ding CQ, Deng WS, Yin XF and Ding XD:
MiR-122 inhibits cell proliferation and induces apoptosis by
targeting runt-related transcription factors 2 in human glioma. Eur
Rev Med Pharmacol Sci. 22:4925–4933. 2018.PubMed/NCBI
|
|
30
|
Chen C, Deng L, Nie DK, Jia F, Fu LS, Wan
ZQ and Lan Q: Circular RNA Pleiotrophin promotes carcinogenesis in
glioma via regulation of microRNA-122/SRY-box transcription factor
6 axis. Eur J Cancer Prev. 29:165–173. 2020. View Article : Google Scholar
|
|
31
|
Fan Y, Ma X, Li H, Gao Y, Huang Q, Zhang
Y, Bao X, Du Q, Luo G, Liu K, et al: miR-122 promotes metastasis of
clear-cell renal cell carcinoma by downregulating Dicer. Int J
Cancer. 142:547–560. 2018. View Article : Google Scholar
|
|
32
|
Nie W, Ni D, Ma X, Zhang Y, Gao Y, Peng C
and Zhang X: miR-122 promotes proliferation and invasion of clear
cell renal cell carcinoma by suppressing Forkhead box O3. Int J
Oncol. 54:559–571. 2019.
|
|
33
|
Ma J, Wu Q, Zhang Y, Li J, Yu Y, Pan Q and
Sun F: MicroRNA sponge blocks the tumor-suppressing functions of
microRNA-122 in human hepatoma and osteosarcoma cells. Oncol Rep.
32:2744–2752. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang Y, Liu Y, Liu W, Li C, Liu Y, Hu W
and Song H: miR-122 inhibits the cervical cancer development by
targeting the oncogene RAD21. Biochem Genet. 60:303–314. 2022.
View Article : Google Scholar
|
|
35
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bossi P, Chan AT, Licitra L, Trama A,
Orlandi E, Hui EP, Halámková J, Mattheis S, Baujat B, Hardillo J,
et al: Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice
guidelines for diagnosis, treatment and follow-up†. Ann
Oncol. 32:452–465. 2021. View Article : Google Scholar
|
|
37
|
Chelakkot C, Chelakkot VS, Shin Y and Song
K: Modulating glycolysis to improve cancer therapy. Int J Mol Sci.
24:26062023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li TE, Wang S, Shen XT, Zhang Z, Chen M,
Wang H, Zhu Y, Xu D, Hu BY, Wei R, et al: PKM2 drives
hepatocellular carcinoma progression by inducing immunosuppressive
microenvironment. Front Immunol. 11:5899972020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhu Z, Tang G and Yan J: MicroRNA-122
regulates docetaxel resistance of prostate cancer cells by
regulating PKM2. Exp Ther Med. 20:2472020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gong H, Zhou L, Khelfat L, Qiu G, Wang Y,
Mao K and Chen W: Rho-associated protein kinase (ROCK) promotes
proliferation and migration of PC-3 and DU145 prostate cancer cells
by targeting LIM kinase 1 (LIMK1) and matrix metalloproteinase-2
(MMP-2). Med Sci Monit. 25:3090–3099. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen X, Yin L, Xu H, Rong J, Feng M, Jiang
D and Bai Y: Knockdown of RhoA expression reverts enzalutamide
resistance via the P38 MAPK pathway in castration-resistant
prostate cancer. Recent Pat Anticancer Drug Discov. 18:92–99. 2023.
View Article : Google Scholar
|
|
42
|
Sato K, Glaser S, Alvaro D, Meng F,
Francis H and Alpini G: Cholangiocarcinoma: Novel therapeutic
targets. Expert Opin Ther Targets. 24:345–357. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu N, Jiang F, He TL, Zhang JK, Zhao J,
Wang C, Jiang GX, Cao LP, Kang PC, Zhong XY, et al: The roles of
MicroRNA-122 overexpression in inhibiting proliferation and
invasion and stimulating apoptosis of human cholangiocarcinoma
cells. Sci Rep. 5:165662015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wu C, Zhang J, Cao X, Yang Q and Xia D:
Effect of Mir-122 on human cholangiocarcinoma proliferation,
invasion, and apoptosis through P53 expression. Med Sci Monit.
22:2685–2690. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Haibe Y, Kreidieh M, El Hajj H, Khalifeh
I, Mukherji D, Temraz S and Shamseddine A: Resistance mechanisms to
anti-angiogenic therapies in cancer. Front Oncol. 10:2212020.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wilkinson L and Gathani T: Understanding
breast cancer as a global health concern. Br J Radiol.
95:202110332022. View Article : Google Scholar :
|
|
47
|
Anwanwan D, Singh SK, Singh S, Saikam V
and Singh R: Challenges in liver cancer and possible treatment
approaches. Biochim Biophys Acta Rev Cancer. 1873:1883142020.
View Article : Google Scholar :
|
|
48
|
Wang SC, Lin XL, Li J, Zhang TT, Wang HY,
Shi JW, Yang S, Zhao WT, Xie RY, Wei F, et al: MicroRNA-122
triggers mesenchymal-epithelial transition and suppresses
hepatocellular carcinoma cell motility and invasion by targeting
RhoA. PloS One. 9:e1013302014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yahya SMM, Fathy SA, El-Khayat ZA,
El-Toukhy SE, Hamed AR, Hegazy MGA and Nabih HK: Possible role of
microRNA-122 in Modulating multidrug resistance of hepatocellular
carcinoma. Indian J Clin Biochem. 33:21–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Duncan AW: Hepatocyte ploidy modulation in
liver cancer. EMBO Rep. 21:e519222020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hsu SH, Delgado ER, Otero PA, Teng KY,
Kutay H, Meehan KM, Moroney JB, Monga JK, Hand NJ, Friedman JR, et
al: MicroRNA-122 regulates polyploidization in the murine liver.
Hepatology. 64:599–615. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Matsumoto T, Wakefield L, Peters A, Peto
M, Spellman P and Grompe M: Proliferative polyploid cells give rise
to tumors via ploidy reduction. Nat Commun. 12:6462021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Matsumoto T: Implications of polyploidy
and ploidy alterations in hepatocytes in liver injuries and
cancers. Int J Mol Sci. 23:94092022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang F, Long J, Li L, Wu ZX, Da TT, Wang
XQ, Huang C, Jiang YH, Yao XQ, Ma HQ, et al: Single-cell and
spatial transcriptome analysis reveals the cellular heterogeneity
of liver metastatic colorectal cancer. Sci Adv. 9:eadf54642023.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Huang FL and Yu SJ: Esophageal cancer:
Risk factors, genetic association, and treatment. Asian J Surg.
41:210–215. 2018. View Article : Google Scholar
|
|
56
|
Zhou K, Yan Y and Zhao S: Esophageal
cancer-selective expression of TRAIL mediated by MREs of miR-143
and miR-122. Tumour Biology: Tumour Biol. 35:5787–5795. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Samarakkody AS, Shin NY and Cantor AB:
Role of RUNX family transcription factors in DNA damage response.
Mol Cells. 43:99–106. 2020.PubMed/NCBI
|
|
58
|
DiNardo CD, Erba HP, Freeman SD and Wei
AH: Acute myeloid leukaemia. Lancet. 401:2073–2086. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhang TJ, Qian Z, Wen XM, Zhou JD, Li XX,
Xu ZJ, Ma JC, Zhang ZH, Lin J and Qian J: Lower expression of bone
marrow miR-122 is an independent risk factor for overall survival
in cytogenetically normal acute myeloid leukemia. Pathol Res Pract.
214:896–901. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yang J, Yuan Y, Yang X, Hong Z and Yang L:
Decreased expression of microRNA-122 is associated with an
unfavorable prognosis in childhood acute myeloid leukemia and
function analysis indicates a therapeutic potential. Pathol Res
Pract. 213:1166–1172. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wang Y, Wang C, Xia M, Tian Z, Zhou J,
Berger JM, Zhang XH and Xiao H: Engineering small-molecule and
protein drugs for targeting bone tumors. Mol Ther. 32:1219–1237.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Liu B, Yao S and Zhou J: Micro-RNA 122 and
micro-RNA 96 affected human osteosarcoma biological behavior and
associated with prognosis of patients with osteosarcoma. Biosci
Rep. 40:BSR202015292020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sun L, Liu X, Pan B, Hu X, Zhu Y, Su Y,
Guo Z, Zhang G, Xu M, Xu X, et al: Serum exosomal miR-122 as a
potential diagnostic and prognostic biomarker of colorectal cancer
with liver metastasis. J Cancer. 11:630–637. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Tang Y, Zhao S, Wang J, Li D, Ren Q and
Tang Y: Plasma miR-122 as a potential diagnostic and prognostic
indicator in human glioma. Neurol Sci. 38:1087–1092. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhan G, Jiang H, Yang R and Yang K:
miR-122 and miR-197 expressions in hepatic carcinoma patients
before and after chemotherapy and their effect on patient
prognosis. Am J Transl Res. 13:6731–6737. 2021.PubMed/NCBI
|
|
66
|
Cochetti G, Cari L, Nocentini G, Maulà V,
Suvieri C, Cagnani R, Rossi De Vermandois JA and Mearini E:
Detection of urinary miRNAs for diagnosis of clear cell renal cell
carcinoma. Sci Rep. 10:212902020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Chen Q, Ge X, Zhang Y, Xia H, Yuan D, Tang
Q, Chen L, Pang X, Leng W and Bi F: Plasma miR-122 and miR-192 as
potential novel biomarkers for the early detection of distant
metastasis of gastric cancer. Oncol Rep. 31:1863–1870. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Nakamura K, Hiyake N, Hamada T, Yokoyama
S, Mori K, Yamashiro K, Beppu M, Sagara Y, Sagara Y and Sugiura T:
Circulating microRNA panel as a potential novel biomarker for oral
squamous cell carcinoma diagnosis. Cancers (Basel). 13:4492021.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Maierthaler M, Benner A, Hoffmeister M,
Surowy H, Jansen L, Knebel P, Chang-Claude J, Brenner H and
Burwinkel B: Plasma miR-122 and miR-200 family are prognostic
markers in colorectal cancer. Int J Cancer. 140:176–187. 2017.
View Article : Google Scholar
|
|
70
|
Deng P, Li M and Wu Y: The predictive
efficacy of serum exosomal microRNA-122 and microRNA-148a for
hepatocellular carcinoma based on smart healthcare. J Healthc Eng.
2022:59145412022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ha SY, Yu JI, Choi C, Kang SY, Joh JW,
Paik SW, Kim S, Kim M, Park HC and Park CK: Prognostic significance
of miR-122 expression after curative resection in patients with
hepatocellular carcinoma. Sci Rep. 9:147382019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kim SS, Nam JS, Cho HJ, Won JH, Kim JW, Ji
JH, Yang MJ, Park JH, Noh CK, Shin SJ, et al: Plasma micoRNA-122 as
a predictive marker for treatment response following transarterial
chemoembolization in patients with hepatocellular carcinoma. J
Gastroenterol Hepatol. 32:199–207. 2017. View Article : Google Scholar
|
|
73
|
Wang S, Liu Y, Feng Y, Zhang J, Swinnen J,
Li Y and Ni Y: A review on curability of cancers: More efforts for
novel therapeutic options are needed. Cancers (Basel). 11:17822019.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
He J, Xie G, Tong J, Peng Y, Huang H, Li
J, Wang N and Liang H: Overexpression of microRNA-122 re-sensitizes
5-FU-resistant colon cancer cells to 5-FU through the inhibition of
PKM2 in vitro and in vivo. Cell Biochem Biophys. 70:1343–1350.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Dai J, Hao Y, Chen X, Yu Q and Wang B:
miR-122/SENP1 axis confers stemness and chemoresistance to liver
cancer through Wnt/β-catenin signaling. Oncol Lett. 26:3902023.
View Article : Google Scholar
|
|
76
|
Cao F and Yin LX: miR-122 enhances
sensitivity of hepatocellular carcinoma to oxaliplatin via
inhibiting MDR1 by targeting Wnt/β-catenin pathway. Exp Mol Pathol.
106:34–43. 2019. View Article : Google Scholar
|
|
77
|
Ma D, Jia H, Qin M, Dai W, Wang T, Liang
E, Dong G, Wang Z, Zhang Z and Feng F: MiR-122 induces
radiosensitization in non-small cell lung cancer cell line. Int J
Mol Sci. 16:22137–22150. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Xu G, Bu S, Wang X and Ge H: MiR-122
radiosensitize hepatocellular carcinoma cells by suppressing cyclin
G1. Int J Radiat Biol. 98:11–17. 2022. View Article : Google Scholar
|
|
79
|
Zhao ZL, Liu C, Wang QZ, Wu HW and Zheng
JW: Engineered exosomes for targeted delivery of miR-187-3p
suppress the viability of hemangioma stem cells by targeting notch
signaling. Ann Transl Med. 10:6212022. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Wu L, Zhou W, Lin L, Chen A, Feng J, Qu X,
Zhang H and Yue J: Delivery of therapeutic oligonucleotides in
nanoscale. Bioact Mater. 7:292–323. 2021.PubMed/NCBI
|
|
81
|
Liang Y, Xu X, Li X, Xiong J, Li B, Duan
L, Wang D and Xia J: Chondrocyte-targeted MicroRNA delivery by
engineered exosomes toward a cell-free osteoarthritis therapy. ACS
Appl Mater Interfaces. 12:36938–36947. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Lou G, Song X, Yang F, Wu S, Wang J, Chen
Z and Liu Y: Exosomes derived from miR-122-modified adipose
tissue-derived MSCs increase chemosensitivity of hepatocellular
carcinoma. J Hematol Oncol. 8:1222015. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Sweef O, Zaabout E, Bakheet A, Halawa M,
Gad I, Akela M, Tousson E, Abdelghany A and Furuta S: Unraveling
therapeutic opportunities and the diagnostic potential of microRNAs
for human lung cancer. Pharmaceutics. 15:20612023. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Li X, Le Y, Zhang Z, Nian X, Liu B and
Yang X: Viral vector-based gene therapy. Int J Mol Sci.
24:77362023. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Yin L, Keeler GD, Zhang Y, Hoffman BE,
Ling C, Qing K and Srivastava A: AAV3-miRNA vectors for growth
suppression of human hepatocellular carcinoma cells in vitro and
human liver tumors in a murine xenograft model in vivo. Gene Ther.
28:422–434. 2021. View Article : Google Scholar :
|
|
86
|
Xiao F, Chen J, Lian C, Han P and Zhang C:
Tumor necrosis factor-related apoptosis-inducing ligand induces
cytotoxicity specific to osteosarcoma by microRNA response
elements. Mol Med Rep. 11:739–745. 2015. View Article : Google Scholar
|
|
87
|
Zhang J, Li D, Zhang R, Peng R and Li J:
Delivery of microRNA-21-sponge and pre-microRNA-122 by MS2
virus-like particles to therapeutically target hepatocellular
carcinoma cells. Exp Biol Med (Maywood). 246:2463–2472. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Shui M, Chen Z, Chen Y, Yuan Q, Li H, Vong
CT, Farag MA and Wang S: Engineering polyphenol-based carriers for
nucleic acid delivery. Theranostics. 13:3204–3223. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Yan Y, Liu XY, Lu A, Wang XY, Jiang LX and
Wang JC: Non-viral vectors for RNA delivery. J Control Release.
342:241–279. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Sendi H, Yazdimamaghani M, Hu M,
Sultanpuram N, Wang J, Moody AS, McCabe E, Zhang J, Graboski A, Li
L, et al: Nanoparticle delivery of miR-122 inhibits colorectal
cancer liver metastasis. Cancer Res. 82:105–113. 2022. View Article : Google Scholar :
|
|
91
|
Guo H, Xu M, Cao Z, Li W, Chen L, Xie X,
Wang W and Liu J: Ultrasound-assisted miR-122-loaded polymeric
nanodroplets for hepatocellular carcinoma gene therapy. Mol Pharm.
17:541–553. 2020.
|
|
92
|
Zeng X, Yuan Y, Wang T, Wang H, Hu X, Fu
Z, Zhang G, Liu B and Lu G: Targeted imaging and induction of
apoptosis of drug-resistant hepatoma cells by miR-122-loaded
graphene-InP nanocompounds. J Nanobiotechnology. 15:92017.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Zhang HT, Sun J, Yan Y, Cui SH, Wang H,
Wang CH, Qiu C, Chen X, Ding JS, Qian HG, et al: Encapsulated
microRNA by gemcitabine prodrug for cancer treatment. J Control
Release. 316:317–330. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Tang Z, Xu Z, Zhu X and Zhang J: New
insights into molecules and pathways of cancer metabolism and
therapeutic implications. Cancer Commun (Lond). 41:16–36. 2021.
View Article : Google Scholar
|
|
95
|
Novikov NM, Zolotaryova SY, Gautreau AM
and Denisov EV: Mutational drivers of cancer cell migration and
invasion. Br J Cancer. 124:102–114. 2021. View Article : Google Scholar :
|
|
96
|
Hsu KH, Wei CW, Su YR, Chou T, Lin YL,
Yang FC, Tsou AP, Hsu CL, Tseng PH, Chen NJ, et al: Upregulation of
RelB in the miR-122 knockout mice contributes to increased levels
of proinflammatory chemokines/cytokines in the liver and
macrophages. Immunol Lett. 226:22–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Nabih HK: The significance of HCV viral
load in the incidence of HCC: A correlation between Mir-122 and
CCL2. J Gastrointest Cancer. 51:412–417. 2020. View Article : Google Scholar
|
